Antibody Drug Conjugate Research Solutions
Antibody-Drug Conjugates (ADCs) couple the precise targeting ability of monoclonal antibodies and the powerful effects of small-molecule cytotoxic drugs. This strategy enhances the precision of cancer treatments while reducing the unwanted side effects commonly seen with traditional therapies. Using high-quality Antibodies and reagents, enhances the outcome of your research immensely.
OriGene's Solution for ADC Research
Explore our options and find the right solution for
your research.
Payloads and Linker
Detecting payloads and linkers is important as it ensures the stability, efficacy, and safety of the therapeutic compound.
These components need to be tracked to verify the successful delivery and release of the payload at the target cell.
ELISA Application Reference Data
ELISA analysis using anti-MMAE antibody and IgG-MMAE molecule. The EC50 is 1.356 ng/ml.
ELISA plates were pre-coated with IgG-Dxd (0.2μg/per well). Serial diluted anti-Dxd monoclonal antibody (
) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for anti-Dxd monoclonal antibody binding with IgG-Dxd is 3.690ng/mlAntibodies Against Linker - Target
Explore OriGene’s monoclonal Anti-CL2A antibody against linker and enhance your research.
ELISA Application Reference Data
ELISA plates were pre-coated with IgG-CL2A (0.2μg/per well). Serial diluted anti-CL2A monoclonal antibody (
) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for anti-CL2A monoclonal antibody binding with IgG-CL2A is 12.57ng/ml.
ADC Internalization Labeling Reagents
The ADC internalization labeling reagents are essential tools for advancing your ADC research. Specifically designed for precision. Further, pH sensitive internalization reagents ensure that the reagents can effectively enter the target cells and release the drug payload at the desired intracellular pH. This specificity enhances the efficacy of the ADC's by minimizing offtarget effects and improving overall results.
Enhance your ADC development process with OriGene's comprehensive internalization labeling reagents for specific and reliable research results.
Reagent Type | Product Number |
---|---|
ADC internalization pH sensitive IgG labeling reagent |
|
ADC internalization pH sensitive IgG labeling reagent plus |
|
ADC Internalization MMAE IgG labeling reagent |
|
Specific Internalization of GPRC5D ADC BMK-AR100090 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).
Biosimilar Antibodies in ADC Research
Biosimilar antibodies are revolutionizing the field of Antibody-Drug Conjugate (ADC) research, providing a cost-effective and highly reliable alternative to innovator biologics. These biosimilars deliver comparable efficacy, safety, and quality to reference monoclonal antibodies, making them an invaluable resource for researchers aiming to develop next-generation ADC therapeutics. With their affordability and consistent performance, biosimilar antibodies are driving innovation in ADC development, accelerating drug discovery, and enhancing accessibility for pharaceutical research teams.
Why Choose Biosimilar Antibodies for ADC Research?
- Cost-Effective Solutions
- Consistent and Reliable Performance
- Accelerated Research Timelines
Selection of OriGene’s Biosimilars:
- Atezolizumab
- Gemtuzumab Ozogamicin
- Praluzatamab
- Magrolimab
Explore of our biosimilars by visiting https://www.origene.com/research-areas/biosimilars